Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $255,594.60 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,060 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.41, for a total transaction of $255,594.60. Following the transaction, the chief operating officer directly owned 503,596 shares of the company’s stock, valued at approximately $6,753,222.36. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total value of $251,210.80.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07.
• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total value of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total value of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total value of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total value of $495,056.00.

Adaptive Biotechnologies Trading Up 0.6%

Shares of ADPT stock opened at $13.58 on Friday. Adaptive Biotechnologies Corporation has a twelve month low of $6.68 and a twelve month high of $20.76. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -33.95 and a beta of 2.19. The firm has a 50-day moving average price of $16.28 and a 200 day moving average price of $15.86.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.23) earnings per share. As a group, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $28,000. Sound Income Strategies LLC acquired a new position in shares of Adaptive Biotechnologies during the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC boosted its position in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. Assetmark Inc. increased its holdings in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies in the 4th quarter valued at $51,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ADPT shares. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Guggenheim raised their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research report on Friday, February 6th. Morgan Stanley initiated coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Finally, TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.